Cencora, Inc. $COR Shares Sold by Berger Financial Group Inc

Berger Financial Group Inc trimmed its holdings in Cencora, Inc. (NYSE:COR) by 18.5% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 18,525 shares of the company’s stock after selling 4,204 shares during the quarter. Berger Financial Group Inc’s holdings in Cencora were worth $5,819,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also made changes to their positions in COR. United Bank lifted its position in Cencora by 4.5% during the second quarter. United Bank now owns 7,032 shares of the company’s stock worth $2,109,000 after buying an additional 305 shares in the last quarter. Nebula Research & Development LLC acquired a new position in Cencora during the second quarter worth $595,000. Treasurer of the State of North Carolina grew its holdings in Cencora by 7.9% in the 2nd quarter. Treasurer of the State of North Carolina now owns 85,534 shares of the company’s stock valued at $25,647,000 after buying an additional 6,244 shares in the last quarter. Diversify Advisory Services LLC grew its holdings in Cencora by 94.1% in the 2nd quarter. Diversify Advisory Services LLC now owns 2,585 shares of the company’s stock valued at $747,000 after buying an additional 1,253 shares in the last quarter. Finally, DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main increased its stake in shares of Cencora by 26.0% in the 2nd quarter. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main now owns 73,452 shares of the company’s stock worth $22,025,000 after acquiring an additional 15,154 shares during the last quarter. 97.52% of the stock is currently owned by institutional investors and hedge funds.

Cencora Stock Performance

NYSE COR opened at $296.43 on Friday. The stock has a market cap of $57.67 billion, a PE ratio of 22.73, a P/E/G ratio of 1.65 and a beta of 0.58. The company has a current ratio of 0.95, a quick ratio of 0.59 and a debt-to-equity ratio of 3.40. Cencora, Inc. has a twelve month low of $244.82 and a twelve month high of $377.54. The stock has a fifty day simple moving average of $277.91 and a 200-day simple moving average of $320.37.

Cencora (NYSE:COR) last issued its quarterly earnings data on Wednesday, May 6th. The company reported $4.75 earnings per share (EPS) for the quarter, missing the consensus estimate of $4.82 by ($0.07). Cencora had a net margin of 0.78% and a return on equity of 135.20%. The company had revenue of $78.36 billion during the quarter, compared to analysts’ expectations of $81.09 billion. During the same quarter last year, the firm posted $4.42 earnings per share. The firm’s quarterly revenue was up 3.9% on a year-over-year basis. Cencora has set its FY 2026 guidance at 17.650-17.900 EPS. Equities analysts anticipate that Cencora, Inc. will post 17.79 earnings per share for the current year.

Cencora declared that its board has approved a share repurchase program on Thursday, May 21st that permits the company to buyback $2.00 billion in outstanding shares. This buyback authorization permits the company to purchase up to 3.9% of its stock through open market purchases. Stock buyback programs are usually a sign that the company’s leadership believes its shares are undervalued.

Cencora Announces Dividend

The business also recently declared a quarterly dividend, which was paid on Monday, June 1st. Stockholders of record on Friday, May 15th were paid a $0.60 dividend. This represents a $2.40 dividend on an annualized basis and a dividend yield of 0.8%. The ex-dividend date of this dividend was Friday, May 15th. Cencora’s payout ratio is 18.40%.

Insider Activity

In related news, Director Lauren M. Tyler acquired 550 shares of the firm’s stock in a transaction dated Monday, June 22nd. The shares were purchased at an average cost of $270.23 per share, for a total transaction of $148,626.50. Following the acquisition, the director owned 4,359 shares in the company, valued at $1,177,932.57. The trade was a 14.44% increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Company insiders own 0.38% of the company’s stock.

Wall Street Analyst Weigh In

Several research analysts have recently commented on the company. Leerink Partners reiterated an “outperform” rating on shares of Cencora in a report on Tuesday, March 17th. Weiss Ratings lowered shares of Cencora from a “buy (b-)” rating to a “hold (c+)” rating in a report on Tuesday. Robert W. Baird cut their price objective on shares of Cencora from $420.00 to $339.00 and set an “outperform” rating for the company in a research report on Thursday, May 7th. Wells Fargo & Company reduced their target price on shares of Cencora from $429.00 to $331.00 and set an “overweight” rating on the stock in a research note on Monday, May 11th. Finally, Barclays decreased their target price on shares of Cencora from $425.00 to $350.00 and set an “overweight” rating on the stock in a report on Wednesday, June 10th. Eleven analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company. Based on data from MarketBeat.com, Cencora presently has a consensus rating of “Moderate Buy” and an average price target of $367.75.

Cencora Profile

Cencora (NYSE:COR) is a global healthcare services and pharmaceutical distribution company that provides end-to-end solutions across the pharmaceutical supply chain. The company’s core activities include wholesale drug distribution, specialty drug distribution, and the operation of specialty pharmacies, complemented by logistics, cold-chain management and other fulfillment services designed to support complex and temperature-sensitive therapies.

Beyond physical distribution, Cencora offers a range of commercial and patient-focused services for pharmaceutical manufacturers and healthcare providers.